The EPS beat and extended cash runway are near-term positives, but with no formal revenue guidance, the stock will likely trade on Phase 1 RT-114 data updates. Monitor for clinical trial milestones and CFO replacement quality.
Price Chart
Executive Summary
Rani Therapeutics reported Q1 2026 GAAP EPS of -$0.04, beating consensus of -$0.06 by 33%, with contract revenue rising to $1.7M (vs $0.2M YoY) from a Chugai collaboration. Cash of $43.4M is expected to fund operations into Q4 2027, supported by an anticipated milestone payment. The EPS beat and improved cash runway are positive, but as a pre-revenue clinical-stage biotech, the impact is tempered by the CFO transition and reliance on pipeline progress.
Key Financial Metrics
Key Facts
- GAAP EPS -$0.04 vs consensus -$0.06 (beat by 33%)
- Contract revenue $1.7M vs $0.2M YoY, driven by Chugai collaboration
- Cash, equivalents & marketable securities $43.4M, expected to fund into Q4 2027
- Net loss narrowed to $8.0M from $12.7M YoY
- CFO Svai Sanford to transition; search for successor underway
- Phase 1 trial of RT-114 (oral GLP-1/GLP-2) for obesity ongoing
Financial Impact
EPS beat by $0.02; revenue increased $1.5M YoY
Risk Factors
- Clinical trial failure or delay for RT-114
- Dilution risk if cash runway requires additional financing
- CFO transition could cause temporary operational uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296128 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 11w ago | 8-K | $0.8200 $0.8645 | ▲ +5.43% | ▲ +6.66% | $0.6172 (−24.73%) |
Jul 15, 2026 14w ago | Press Release | $0.6770 $0.8028 | ▲ +18.58% | ▲ +16.24% | $0.6172 (−8.83%) |
May 15, 2026 23w ago | Press Release | $0.9720 $0.7597 | ▼ −21.84% | ▼ −23.42% | $0.6172 (−36.50%) |
Mar 26, 2026 30w ago | Press Release | $0.8110 $0.8900 | ▲ +9.74% | ▼ −3.00% | $0.6172 (−23.90%) |
Mar 19, 2026 31w ago | Press Release | $1.13 $0.9740 | ▼ −13.81% | ▼ −23.12% | $0.6172 (−45.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers